Conference Track

First-Line Therapy and Switch Strategies

Source: CCO Official Conference Coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

Capsule Summaries

GS934: Virologic Suppression Sustained Through 144 Weeks in HIV-Infected Patients Treated With Tenofovir/Emtricitabine Plus Efavirenz
Switching Zidovudine/Lamivudine to Tenofovir/Emtricitabine Demonstrates Safety Benefit Without Compromising Virologic Suppression in HIV-Infected Patients Receiving Efavirenz
GEMINI Study: Efficacy and Safety of Boosted Saquinavir Regimen Appears Similar to Boosted Lopinavir in Therapy-Naive Patients at 24 Weeks
Raltegravir Demonstrates Rapid and Sustained Antiretroviral Efficacy in Treatment-Naive HIV-Infected Patients: 48-Week Results
ALERT Study: Novel Boosted-Fosamprenavir Regimen Provides Similar Efficacy to Boosted-Atazanavir Regimen in Therapy-Naive Patients at 48 Weeks
Interim Results of IMANI-2: Lopinavir/Ritonavir Monotherapy Achieves Sustained Virologic Suppression in Treatment-Naive Patients
Patients With Early ART Initiation Spend Less Time at Low CD4+ Cell Counts and are at Decreased Risk for Opportunistic Disease, Death, and Serious Adverse Events
Several Clinical, Immunologic Markers Predict for Non-AIDS–Related Causes of Death in cART Era
Antiretroviral Therapy With 2 Drugs Found as Effective as Standard Triple-Drug Therapy
Higher Rate of Treatment Failure With Switch to Fixed-Dose Abacavir/Lamivudine vs Tenofovir/Emtricitabine in Virally Suppressed Patients on Lamivudine-Containing HAART
Tenofovir-Containing Antiretroviral Therapy Shown Safe and Effective in 6-Year Extension Study
AI424-089: Similar Virologic Efficacy With Boosted vs Unboosted Atazanavir in Therapy-Naive Patients at Week 96, but More Virologic Failures With Unboosted Regimen
Maraviroc Fails to Meet Rigorous Noninferiority Criteria Compared With Efavirenz in First-Line Therapy

Expert Analysis

First-Line Therapy and Switch Strategies

Faculty:

David A. Cooper, MD, DSc
Joel E. Gallant, MD, MPH
Kathleen E. Squires, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent data on first-line antiretroviral therapy options
Describe the results of recent clinical studies concerning switch strategies
Describe findings concerning antiretroviral therapy initiation in treatment-naive populations

CREDIT INFORMATION

Release Date: 09/27/07

Expiration Date: 09/26/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing contact hours

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.